Early trial data for Moderna’s mRNA flu vaccine disappoints
Biotechnology company Moderna has announced the first preliminary data from its ongoing Phase 1/2 human trial testing an mRNA vaccine designed to target four strains of influenza. The vaccine was found to be safe and effective at generating antibody re… Continue reading Early trial data for Moderna’s mRNA flu vaccine disappoints